Sumitomo Pharmaceuticals New Distributor for Hibitane
Zeneca Yakuhin K.K., headed by president Bruno Angelici, AstraZeneca K.K., headed by president Bruno Angelici, and Sumitomo Pharmaceuticals Co. Ltd., headed by president Masaaki Yokotsuka, all headquartered in Osaka, have agreed to transfer the promotion and distribution of Hibitane products from Zeneca Yakuhin K.K. to Sumitomo Pharmaceutical Co., Ltd. effective October 1, 2000.
Hibitane, a disinfectant originally developed by AstraZeneca PLC (formerly ICI) and now widely used around the world, has been licensed to Zeneca Yakuhin in Japan.
As part of their strategy for the future, Zeneca Yakuhin and AstraZeneca, both part of the AstraZeneca Group, have reached the conclusion that transferring the Hibitane line to Sumitomo Pharmaceutical will provide better business opportunities.
Sumitomo Pharmaceuticals has been closely allied with the AstraZeneca Group under a toll manufacturing agreement for AstraZeneca products, including Hibitane, and hopes that this newly acquired group of disinfectants will enhance its product line.
Sumitomo Pharmaceuticals Co., Ltd., while taking over the manufacture and distribution of Hibitane, will continue as always to strive to provide detailed medical information and quality pharmaceuticals, including the newly-added Hibitane, scheduled to join its product offerings on October 1, 2000.Products to be transferred to Sumitomo:
|Hibitane 5% liquid|
|Hibitane gluconate liquid|
Hibitane Obstetric Cream and Hibitane Disinfectant Cream will continue to be distributed by AstraZeneca group companies.